Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05211570 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG AB8939
Study Locations (10)
Other
- Institut Paoli Calmettes — Marseille
- National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit — Athens
- General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante) — Alicante
- Hospital San Pedro de Alcantara — Cáceres
- Hospital Universitario 12 de Octubre — Madrid
- Hospital Universitario Quirónsalud — Madrid
- MD Anderson Cancer Center Madrid — Madrid
- Clínica Universidad de Navarra — Pamplona
- Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío) — Seville
Texas
- MD Anderson Cancer Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05211570
The ClinicalTrials.gov registry entry for NCT05211570 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AB Science, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 2 interventions — of which Venetoclax is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05211570 reports 10 study locations spanning 2 distinct geographic areas — top geographies include Other, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05211570 about?
NCT05211570 is a clinical study titled "AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
What is the current status of trial NCT05211570?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2022-06-01. Estimated completion is 2026-12.
What conditions does trial NCT05211570 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05211570?
The interventions under investigation include: Venetoclax (DRUG), AB8939 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05211570?
This trial is sponsored by AB Science, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05211570 being conducted?
This trial has 10 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.